Cell. Mol. Life Sci.
DOI 10.1007/s00018-015-1847-9
Cellular and Molecular Life Sciences
REVIEW
The PRMT5 arginine methyltransferase: many roles
in development, cancer and beyond
Nicole Stopa • Jocelyn E. Krebs • David Shechter
Received: 15 November 2014 / Revised: 10 January 2015 / Accepted: 29 January 2015
Springer Basel 2015
Abstract Post-translational arginine methylation is responsible for regulation of many biological processes. The
protein arginine methyltransferase 5 (PRMT5, also known
as Hsl7, Jbp1, Skb1, Capsuleen, or Dart5) is the major
enzyme responsible for mono- and symmetric dimethylation of arginine. An expanding literature demonstrates its
critical biological function in a wide range of cellular
processes. Histone and other protein methylation by
PRMT5 regulate genome organization, transcription, stem
cells, primordial germ cells, differentiation, the cell cycle,
and spliceosome assembly. Metazoan PRMT5 is found in
complex with the WD-repeat protein MEP50 (also known
as Wdr77, androgen receptor coactivator p44, or Valois).
PRMT5 also directly associates with a range of other
protein factors, including pICln, Menin, CoPR5 and RioK1
that may alter its subcellular localization and protein substrate selection. Protein substrate and PRMT5–MEP50
post-translation modifications induce crosstalk to regulate
PRMT5 activity. Crystal structures of C. elegans PRMT5
and human and frog PRMT5–MEP50 complexes provide
substantial insight into the mechanisms of substrate
recognition and procession to dimethylation. Enzymological studies of PRMT5 have uncovered compelling
insights essential for future development of specific
N. Stopa J. E. Krebs (&)
Department of Biological Sciences, University of Alaska
Anchorage, 3211 Providence Drive, Anchorage,
AK 99508, USA
e-mail:
[email protected]
D. Shechter (&)
Department of Biochemistry, Albert Einstein College
of Medicine of Yeshiva University, 1300 Morris Park Avenue,
Bronx, NY 10461, USA
e-mail:
[email protected]
PRMT5 inhibitors. In addition, newly accumulating evidence implicates PRMT5 and MEP50 expression levels
and their methyltransferase activity in cancer tumorigenesis, and, significantly, as markers of poor clinical
outcome, marking them as potential oncogenes. Here, we
review the substantial new literature on PRMT5 and its
partners to highlight the significance of understanding this
essential enzyme in health and disease.
Keywords Protein arginine methyltransferase
Histones Spliceosome Development Cancer
Introduction
Protein arginine methyltransferases (PRMTs) transfer
methyl groups from S-adenosylmethionine (AdoMet or
SAM) to a guanidine nitrogen of protein arginine resulting
in the reaction products methylarginine and S-adenosylhomocysteine (SAH) (reviewed in [1]). There are four
types of PRMTs: type I PRMTs catalyze x-NGmonomethylarginine (MMA) and asymmetric x-NG, NGdimethylarginine (aDMA); type II PRMTs catalyze MMA
and symmetric x-NG, N0 G-dimethylarginine (sDMA); type
III PRMTs are capable of only monomethylation; and Type
IV generates d-NG-monomethylarginine (Fig. 1; type IV
activity, limited to yeast Rmt2 [2], is not shown). PRMT1,
2, 3, 4, 6, and 8 are Type I, while PRMT5 and possibly
PRMT7 are Type II PRMTs [3–6]. Recent proteomic
analysis of human tissues reveals differences in PRMT
family protein expression (Fig. 2) [7], with higher expression in fetal tissues for all PRMTs. PRMT2, 3, 6, 7, and
8 exhibit tissue-specific expression patterns, while PRMT1,
4, and 5 exhibit more universal expression. PRMT5’s
partner methylosome protein 50 (MEP50) has similar
123
N. Stopa et al.
Fig. 1 Arginine methylation states catalyzed by the family of protein
arginine methyltransferases (PRMTs). The guanidinium side chain of
arginine residues in proteins is positively charged. It can accept a
monomethyl addition, catalyzed by the family of Type I, II, and III
PRMTs through transfer from the S-adenosylmethionine (SAM or
AdoMet) cosubstrate, resulting in a x-NG monomethylated arginine
(MMA) and S-adenosylhomocysteine (SAH). Type I PRMTs, comprising the majority of PRMT enzymes, can further catalyze the x-NG
monomethylation to x-NG, NG asymmetric dimethylarginine
(aDMA), consuming SAM and producing SAH. PRMT5, a Type II
enzyme, catalyzes the x-NG monomethylation to x-NG, N0 G asymmetric dimethylarginine (sDMA), also consuming SAM and
producing SAH. Type III enzymes are incapable of processing to
dimethylation. Methylation does not alter the positive charge on the
arginine guanidinium side chain
Fig. 2 PRMT5 and MEP50 are broadly expressed in somatic and
embryonic tissues. The human proteome map, analyzed by total
proteome mass spectrometry (http://www.humanproteomemap.org
[7]), was queried for the PRMT family of proteins which showed
that they are distinctly expressed in a range of human tissues and
cells. The relative protein abundances for the PRMT1-8 (CARM1 is
the name for PRMT4) are shown in a heatmap, with white representing low protein abundance and dark red representing higher
abundance, with a ten-step range indicated in the legend. PRMT5 is
bolded and boxed, as is its MEP50 cofactor. Note that PRMT5 and
MEP50 are most highly expressed in fetal tissue and that their expression patterns are quite similar
expression to PRMT5. PRMT9, newly annotated in NCBI,
is still undescribed. The initially annotated PRMT9 is now
correctly identified as an F-box protein, FBXO11 [8].
PRMT5 is the primary Type II arginine methyltransferase and found in all eukaryotic species investigated
(Fig. 3a). The S. cerevisiae homolog of PRMT5 is histone
synthetic lethal 7 (Hsl7); the S. pombe homolog is Shk1
kinase-binding protein 1 (Skb1) [9, 10]. Hsl7’s synthetic
lethality with histones that led to its name likely had no
connection with histone methylation, as no evidence of
123
The PRMT5 arginine methyltransferase
A
B
D
C
Fig. 3 PRMT5 domain organization and structure are evolutionarily
conserved. a A range of PRMT5 protein sequences across eukaryotic
species [Homo sapiens (human), Xenopus laevis (frog), Danio rerio
(fish), Drosophila melanogaster (fly), Arabidopsis thaliana (plant),
Caenorhabditis elegans (worm)] was aligned using the MAFFT
algorithm and the Pam120 similarity index and represented in a
heatmap from white (\60 % similarity) to dark blue (100 %
similarity). Alignment gaps are indicated by a line, and overall
identity is shown on the right. The major domains and interfaces are
indicated above and below the sequences. Asterisk indicates sequence
insertion in C. elegans PRMT5 that prohibits tetramerization. b The
human prmt5 gene has multiple splice variants, as shown from the
NCBI human genome sequence. All the variants are in the N-terminal
domain of the encoded protein. c Subunit arrangement of the heterooctameric PRMT5–MEP50 structure shown in cartoon form, with the
head-to-tail N-terminal and C-terminal PRMT5 arrangement shown
by ‘‘N-’’ and ‘‘-C’’. d Ribbon diagram of a monomer of human
PRMT5 (PDB:4GQB) with the domains and substrate-binding sites as
indicated
histone arginine methylation exists in S. cerevisiae. Human
PRMT5 was first identified as Jak-binding protein 1
(JBP1), and shown to methylate, among many cellular
proteins, histones H2A and H4 on Arg3 and histone H3 on
Arg8 [11–13] (Table 1). Histones H2A and H4 share a
conserved targeted N-terminal sequence: SGRGK….
Multiple PRMT5 splice variants are found in human cells,
although evidence for translated proteins from these shorter
mRNAs is lacking (Fig. 3b).
In this review, we highlight and interpret the literature on PRMT5, its partners, targets, structure, and
enzymology. We address PRMT5’s role in stem cells
and primordial germ cells, differentiation, and animal
development. In the context of PRMT5’s wide-ranging
biological roles, we explore the extensive literature
implicating PRMT5 in a large number of cancers.
While hints of PRMT5’s significance for tumorigenesis
have been apparent for some time, we argue here that
the sheer abundance of evidence shows that PRMT5 is
now a compelling target for clinical screening and,
hopefully, for future chemotherapeutic approaches. A
recent review of the function of all PRMTs in chromatin organization provides a complementary view of
the specific function of arginine methylation in nuclear
function [14].
MEP50: a critical PRMT5 cofactor
The majority of vertebrate PRMT5 complexes contain
MEP50, a 7-bladed WD40 repeat (tryptophan, aspartic
acid) b-propeller protein. MEP50 is also known as Wdr77
or androgen receptor coactivator p44, by which it is referred to in the cancer literature [15–24]. MEP50 directly
binds PRMT5 and greatly enhances PRMT5’s histone
methyltransferase ability, primarily through increased
123
N. Stopa et al.
Table 1 Major PRMT5 protein substrates and their function
PRMT5 substrate
Biological function of arginine methylation by PRMT5
References
Histone H2A and H4 R3
Transcriptional repression
[54, 56, 61, 62, 64, 65, 67, 68, 76, 77, 103,
162]
Histone H3 R2
Transcriptional repression
[4, 80, 163]
Histone H3 R8
Transcriptional repression
[13, 57, 60, 82, 122, 164]
Spliceosome Sm proteins
Facilitates spliceosomal assembly
[41, 44, 49, 108, 165–169]
Ribosomal protein
RPS10
Facilitates ribosomal assembly
[170]
[71, 143]
p53
Facilitates survival and cell cycle arrest over apoptosis
FEN1
Facilitates PCNA binding and DNA replication and repair
[171]
Nucleoplasmin
Enriched in early development; unknown function
[37]
Nucleolin
RNA binding; unknown function
[108, 109]
EGFR
Reduces autophosphorylation and EGFR activation
[145]
EBNA
Methylation stimulates Epstein–Barr nuclear antigen promoted
transcription
[153, 154]
affinity for protein substrate (D.S., manuscript under review). The arrangement of MEP50 in complex with
PRMT5 is illustrated in Fig. 3c.
Structure and enzymology of PRMT5 and MEP50
Structural insight into general PRMT mechanisms was
recently reviewed [25]. The C. elegans, Xenopus, and human PRMT5 all contain a triosephosphate isomerase (TIM)
barrel on the N-terminus, a middle Rossmann-fold, and a
C-terminal b-barrel containing a dimerization domain
(Fig. 3d). CePRMT5 forms a homodimer in which the
dimerization arm of one monomer interacts with residues
contained in the TIM barrel of the other monomer, forming
a ring [26]. This head-to-tail ring-shaped homodimer is
conserved in all of the solved Type I PRMT structures [27–
33]. In contrast, the human and Xenopus PRMT5s form a
heterooctomeric complex composed of four PRMT5 proteins and four MEP50 proteins (Fig. 3c) [34, 35]. The
PRMT5 molecules form two dimers in the head-to-tail
arrangement typical of PRMTs. One of the two dimers in
the human and Xenopus PRMT5 tetramer is similar to the
C. elegans dimer and contains a number of conserved hydrogen bonds. The second dimer interface, unique to the
human and Xenopus PRMT5 tetramer, contains hydrogen
bonds not seen in the C. elegans dimer. Furthermore, a
sequence insertion found in C. elegans would prevent this
dimerization of PRMT5 to a tetramer (noted by asterisk in
Fig. 3a). The PRMT5 tetramer forms the core of the
complex and MEP50 interacts with PRMT5 through the
N-terminal TIM barrel domains. A monomer of human
PRMT5 is illustrated in Fig. 3d, showing the domain
123
structures as well as the locations of the SAM and histone
peptide substrates within the crystal.
The PRMT5–MEP50 complex has a higher level of
methyltransferase activity compared to PRMT5 alone [35].
This could be due to MEP50 having a positive allosteric
effect on the binding of cofactor and protein or SAM substrates by PRMT5 and/or MEP50 being necessary to present
protein substrate to PRMT5. The latter is supported by experiments demonstrating MEP50 interaction with H2A and
H4 [34, 36], and that excess MEP50 inhibits methyltransferase activity, consistent with MEP50 sequestering substrate
from the enzyme [34]. The PRMT5 catalytic site is also
oriented toward the cross-dimer paired MEP50 and electron
microscopy-localized substrate density on MEP50 [34].
PRMT5–MEP50 is nonprocessive, as production of the
dimethylated H4 peptide product is dependent on the
concentration of the monomethylated peptide exceeding
that of the unmethylated substrate [35, 37]. Thompson and
colleagues [38] demonstrated that CePRMT5 is truly distributive. This is in contrast to PRMT1, for which
monomethylated and dimethylated products are observed
despite the presence of excess unmodified substrate, indicating PRMT1 uses a partially processive mechanism [39].
A conserved phenylalanine in the C. elegans PRMT5
catalytic site is essential for specifically catalyzing symmetric dimethylation by structural orientation of the
monomethylated arginine substrate [26]. Mutation of a
catalytic site Met to Phe remodels PRMT1 to produce
symmetric dimethylation, although production of the
symmetric dimethylarginine has a higher energy barrier
[40]. This reveals that the catalytic mechanisms for production of the various methylarginine products are similar
and are regulated through structural and energetic means.
The PRMT5 arginine methyltransferase
PRMT5 and the major spliceosome
PRMT5–MEP50, along with PRMT7, play important roles
in the splicing of mRNA through methylating spliceosomal
proteins [41]. Sm proteins D1, D3, and B/B0 are symmetrically dimethylated on their C-terminus by the
methylosome, PRMT5–MEP50 in complex with pICln
(chloride channel nucleotide sensitive 1A, Fig. 4) [42, 43].
pICln binds the Sm domain and acts as an assembly
chaperone [44–47]. PRMT5-catalyzed sDMA of Sm D1,
D3, and B/B0 dramatically increases binding of these three
proteins to the Tudor domain-containing protein SMN (survival of motor neuron), the product of the spinal
muscular atrophy gene [42, 43]. SMN is part of a complex
consisting of at least six other subunits, and is responsible
for loading the seven Sm proteins onto the snRNA [48–51].
There is some evidence the snRNPs can assemble without
the SMN complex in vitro [52], leading to some debate as
to whether the symmetric dimethylation of Sm proteins is
necessary. However, in vivo the SMN–PRMT5 relationship most likely acts as a chaperone that prevents the
misassembly of Sm proteins to non-target RNAs and
blocks the aggregation of Sm proteins [51]. A conditional
PRMT5 knockout in mouse neural stem/progenitor cells
(NPCs) shows PRMT5 is necessary for correct splicing:
absence of PRMT5 leads to selective retention of introns
and skipping of exons with weak 50 donor sites [53].
Histone methylation by PRMT5 and its function
in transcriptional regulation
Histone tail modifications are major components of the
epigenetic regulation of gene transcription. PRMT5 symmetrically dimethylates H2AR3, H4R3, H3R2, and H3R8
in vivo, all of which are linked to a range of transcriptional
regulatory events (Fig. 5) [11, 13, 54–60]. Specific gene
targets include cyclin E1 [59], Rb [57], and ribosomal
genes [61]. In Arabidopsis, PRMT5 is recruited to the
CORYNE locus to down-regulate its expression and regulate shoot apical meristem phenotypes [62] and the
FLOWERING LOCUS C to control flowering time [63].
PRMT5 coordinates with a range of Mediator complex
subunits to dimethylate H4R3 at promoter regions of immune response genes and C/EBPb target genes [64].
Conversely, PRMT5 methylation of histone H3R2 recruits
Wdr5 and the MLL complex, stimulating H3K4 methylation and euchromatin maintenance [4].
PRMT5 selectively methylates cytosolic H2AR3 in ES
cells, but not H4R3 [65]. The distinction between roles for
Fig. 4 PRMT5 methylation and
regulation of the spliceosome. A
cartoon representation of the
function of PRMT5 methylation
of splicing proteins in the
cytoplasm. Methylated
substrates are represented with a
red ‘‘–CH3’’. PRMT5, in
complex with MEP50 and
pICln, form the methylosome
that targets spliceosomal
subunits for methylation. pICln
then chaperones the subunits to
the SMN complex, resulting in
proper targeting of RNAs to be
spliced
123
N. Stopa et al.
Fig. 5 PRMT5 is targeted to multiple histone and nuclear targets by
cofactors. A cartoon representation of the function of PRMT5
methylation of nuclear proteins (nucleus represented by pale yellow).
Methylated substrates are represented with a red ‘‘–CH3’’. Histones,
the protein component of chromatin, are synthesized and then
transported to the nucleus. PRMT5–MEP50 targets newly synthesized
histone H2A in the cytoplasm and may target soluble H4 in the
nucleus (both H2A and H4 are methylated on R3 in the sequence
N-SGRGK… as shown in the cartoon), as well as transcription factors
such as p53 and NF-jB. PRMT5-methylated H2A and H4 are then
deposited into chromatin (DNA wrapped around histone proteins,
with histone N-terminal tails indicated in the cartoon). Alternative
binding partners for PRMT5 (RioK1 in the cytoplasm, CoPR5 and
Menin in the nucleus) may displace one or more MEP50 molecules
and alter the targeting of PRMT5 toward substrates as shown,
including histone H3 on R2 or R8 in the sequence
N-ARTKQTARKST…
H2A and H4 R3 methylation by PRMT5 suggests that each
histone tail and targeted arginine has a unique function and
will require future work to disentangle. However, since
H2A and H4 have the same ‘‘NH2-SGRGK…’’ site of
methylation, most available antibodies recognize both
methylated histones making discrimination difficult. The
few genome-wide studies of PRMT5-catalyzed histone
methylation on H2A/H4 R3me2s demonstrate global enrichment [66], with specific enrichment at GC-rich
promoter regions in mouse embryonic fibroblasts [67]. In
contrast, enrichment on non-GC satellite DNA [68] as well
as a modest anti-correlation with H3K36me3 [56] is observed in other studies. Girardot et al. [67] used an
antibody lot that specifically recognizes H4R3me2s but not
H2AR3me2s, possibly explaining these distinct observations. Future experimentation with a range of highly
specific histone methylarginine antibodies, including
monomethylarginine, and performed in a range of cell
types and organisms, will help clarify the function of histone arginine methylation in gene regulation.
PRMT5 also regulates transcription and many downstream events through methylation of transcription factors,
such as NF-jB [69, 70], p53 [71], and E2F-1 [72]. PRMT1and PRMT5-catalyzed asymmetric and symmetric
dimethylarginine have distinct roles in activating or suppressing apoptotic activity, respectively, of E2F-1 through
recruitment of the p100-TSN Tudor domain to symmetric
dimethylarginine [72].
123
The PRMT5 arginine methyltransferase
Readers of symmetric dimethylation
Methylated arginine is translated into a meaningful cellular
signal through recognition (‘‘reading’’) by effector proteins
or by inhibiting binding of effector proteins (recently reviewed in [73]). Tudor domain-containing proteins are the
primary direct readers of methylarginine. The splicing
factors methylated by PRMT5 are recognized by SMN
proteins containing Tudor domains [74] while PRMT5methylated PIWI proteins are recognized by the SND1
Tudor-containing protein [75]. Histone H4R3me2s
specifically recruits the DNA methyltransferase DNMT3A
to chromatin domains via its ADD (ATRX-DNMT3DNMT3L) domain to suppress gene expression [76, 77].
However, another report was unable to reproduce this interaction [78], so further study is necessary. In contrast,
H4R3me2s or H4R3me2a can interfere with the ability of
the Signal Recognition Particle (SRP) proteins SRP68 and
SRP72 to bind the H4 tail [79].
PRMT5 also methylates histone H3R2 and recruits
Wdr5, a WD40-repeat protein and essential component of
MLL (mixed lineage leukemia lysine methyltransferase)
complexes, to promote H3K4 methylation and downstream
gene activation [4, 80]. Wdr5 quantitatively binds
H3R2me2s, but does not bind H3R2me2a, providing a
unique switch between recruitment states based on the
change in methylarginine. The crystal structure of Wdr5
bound to H3R2me2s demonstrates that the symmetric
dimethylarginine displaces water within the binding cavity,
substantially enhancing the interaction and suggesting that
WD-repeat proteins may function to distinguish between
different post-translation modification (PTM) states [4].
Interaction of PRMT5 with ATP-dependent chromatin
remodelers: function in transcriptional regulation
PRMT5 methylates histones and interacts with ATP-dependent chromatin remodelers to either enable or repress
gene expression, depending on the cellular context (Fig. 5)
(reviewed in [81]). PRMT5 localizes to the promoter of the
early MyoD-induced gene myogenin, and also coimmunoprecipitates with MyoD and the chromatin remodeler
ATPase Brg1 [82]. Furthermore, H3R8 dimethylation catalyzed by PRMT5 at the myogenin promoter is a necessary
prerequisite for the binding and chromatin remodeling activity of Brg1, which in turn is necessary for the binding of
MyoD. Antisense-mediated knockdown of PRMT5
positively and negatively regulated many genes, including
several with antiproliferative and tumor suppressor activity
[13]; in this study, PRMT5 was shown to associate with the
BRG1 and BRM chromatin remodelers and methylate
promoter H3R8 to inhibit tumor suppressors. PRMT5 also
associates with the NuRD remodeling complexes that
contain the methyl-CpG-binding domain protein 2 (MBD2)
[83]. Together these studies suggest that gene repression or
activation by PRMT5 is context dependent.
Other PRMTs associate with chromatin remodeling
complexes as well. PRMT4 is required to facilitate SWI/
SNF chromatin remodeling activity for late but not early
gene expression in skeletal muscle differentiation, in contrast to PRMT5 promotion of early gene expression [84,
85]. These data demonstrate that arginine methyltransferases sequentially cooperate with chromatin remodeling
complexes.
Role of PRMT5 in development
PRMT5 participates in both early and late developmental
pathways. In murine early development, PRMT5 is maternally inherited in the oocyte cytoplasm until the first
cellular differentiation event when it translocates to the
nucleus [65]. Prmt5-/- murine embryos suffer early embryonic lethality and are incapable of producing embryonic
stem ES cells. RNAi knockdown of PRMT5 in ES cells
results in down-regulation of pluripotency-associated genes
and up-regulation of differentiation-associated genes [65].
In human stem cells, PRMT5 is only required for proliferation, and not pluripotency, through methylation of the
cell cycle-regulated p57 [86]. Mep50 null mice are
similarly embryonic lethal [21, 24], further supporting the
essential function of the intact PRMT5–MEP50 complex.
In Xenopus laevis embryos, prmt5 is abundant until
zygotic stage 8, when transcript levels drop precipitously
coincident with the onset of zygotic transcription [37].
PRMT5-methylated histones and histone chaperones are
heavily enriched in early frog embryos [87–89]. PRMT5–
MEP50 methylates pre-deposition histones H2A/H2A.X-F
and H4 and the maternal histone chaperone nucleoplasmin
on a conserved motif (‘‘GRGxK’’) [37]. These observations
are consistent with a maternal and early zygotic role for
PRMT5–MEP50 in regulating embryonic chromatin
assembly and globally repressing zygotic transcription.
PRMT5 function in primordial germ cell
and keratinocyte differentiation
PRMT5 also plays a role in a number of tissue-specific
differentiation pathways, including primordial germ cells,
keratinocyte, muscle, and nerve cell differentiation [81, 82,
84, 90–94].
In germ cell development, PRMT5 methylates Piwi
proteins and regulates their subsequent binding to Tudor
domain-containing proteins in an sDMA-dependent fashion
123
N. Stopa et al.
[95–99]. Piwi proteins are primarily expressed in the
germline lineage and interact with small non-coding RNAs,
piRNAs [100]. piRNAs complement transposable DNA
elements and other genes, leading to their silencing, which
is essential for normal gametogenesis [101]. For example,
in Drosophila, either a prmt5 homozygous null mutant or a
loss of function Tudor mutation causes transposon upregulation [102]. PRMT5 histone methylation is also required for suppressing transposable elements during
murine PGC demethylation [103]. PRMT5 interacts with
the transcriptional repressor Blimp1, an essential component of primordial germ cell (PGC) induction [54, 104].
Association of PRMT5 and Blimp1 in the nucleus of PGCs
results in increasing levels of H2A/H4 R3me2s and upon
the subsequent translocation of PRMT5 and Blimp1 to the
cytoplasm H2A/H4 R3me2s is almost completely lost [54].
This coincides with the down-regulation of pluripotency
genes and the expression of Dhx38, an RNA helicase,
which may recruit PRMT5 and Blimp1 to specific DNA
sequences [54, 105]. These results suggest that the Blimp1/
PRMT5 complex has an essential role in maintaining the
PGC lineage during the migration of the cells into the
gonads [106]. Alternatively, PRMT5’s function may be at
the end of PGC programming to regulate RNA splicing
[107].
In human keratinocyte differentiation involucrin gene
expression is partially controlled by PKC-d suppression of
PRMT5 [92]. PRMT5 is part of the p38-d complex and
functions through suppression of p38-d phosphorylation
and sDMA modification of an as yet unidentified protein
[92].
Modulation of PRMT5 activity through binding
partners, post-translational modification crosstalk,
and subcellular localization
PRMT5 activity and localization are regulated in multiple
ways, including binding partners (Table 2), PTMs, subcellular localization, and microRNAs (miRNA).
Binding partner regulation of PRMT5
PRMT5 binds to pICln or the Rio domain-containing
protein RioK1 in a mutually exclusive manner on
PRMT5’s N-terminal domain, and likely serves to specify
substrate choice [108] (Fig. 5). The RNA-binding protein
nucleolin interacts only with the C-terminus of RioK1, and
not with PRMT5 or MEP50. RioK1 functions similarly to
pICln and MEP50 by acting as an adaptor protein [108]. In
further support of the biological connection between
PRMT5 and nucleolin, the AS1411 aptamer that targets
nucleolin alters the subcellular localization of the PRMT5–
123
nucleolin complex within prostate cancer cells, potentially
providing a molecular basis for some AS1411 effect on
cancer cell proliferation [109]. RioK1 is exclusively located in the cytoplasm, which may further control the
temporal and spatial activity of PRMT5. Therefore, coupled subcellular localization of adaptor proteins could be
an important mechanism to regulate PRMT5 activity.
Other vertebrate-specific binding partners also regulate
or target PRMT5 activity to specific substrates, including
Menin/Men1, pICln, RioK1, and CoPR5 [44, 45, 93, 108,
110–114]. CoPR5 (cooperator of PRMT5), to date only
found in mammals, binds histones in the nucleus and recruits PRMT5 to nucleosomes [114]. CoPR5 binding to
PRMT5 is necessary for myogenic differentiation, possibly
through altered targeting of PRMT5 [93]. Menin, a unique
adapter protein found in MLL complexes to target histone
K4 trimethylation and frequently mutated in endocrine
tumors, was shown to directly bind to the N-terminus of
PRMT5 and target H4R3me2s at a specific promoter [110].
One compelling hypothesis supported by published interaction data and our structural modeling is that RioK1
and Menin may displace one or more MEP50 molecules
from the PRMT5 complex, altering PRMT5 targeting while
maintaining MEP50 in part of the heterocomplex to promote histone or other methylation (Fig. 5). This hypothesis
could explain why PRMT5 forms a tetramer in vertebrates:
to maintain MEP50 interaction and allow simultaneous
binding of additional cofactors. Another mechanism for
regulation of PRMT5 binding is via splicing. Alternative
transcripts of PRMT5 missing exons in the N-terminus of
PRMT5, which binds MEP50, Menin, Riok1 and plCln, are
known (Fig. 3b) [115]. Future studies may reveal altered
PRMT5 protein production from these transcripts that alter
partner binding.
PTM crosstalk modulation of PRMT5
PRMT5–MEP50 substrate PTMs can affect methyltransferase activity. SWI/SNF-associated PRMT5 methylates
hypoacetylated H3 and H4 more efficiently than hyperacetylated H3 and H4 [58]. Neighboring H4 lysine
acetylation marks stimulate PRMT5 activity in contrast to
their inhibition of PRMT1 activity [116], while high-density histone peptide arrays document an elaborate crosstalk
of activity regulation [34]. We modeled acetylation on
H4K5 in the crystal structure of human PRMT5 and
demonstrate that it would likely be stabilized in position
compared to the hydrogen bonding with the structural
water molecule in the unacetylated H4K5 in the structure
(Fig. 6a, b). H2AS1 and H4S1 phosphorylation also inhibit
PRMT5 activity [34]; as shown in Fig. 6c, the bulkier S1ph
may be hindered from binding and/or may be electrostatically repulsed from the neighboring PRMT5 Y304.
The PRMT5 arginine methyltransferase
Table 2 Major PRMT5 interacting proteins and their function
PRMT5 binding
partnera
Biological
function
References
MEP50 (also known as Wdr77/Androgen Essential for PRMT5 histone methylation;
Coactivator p44)
always found bound to PRMT5 in metazoans
[16, 22, 23, 34–37, 65, 83, 118, 125, 129,
167, 172, 173]
pICln
Contributes to spliceosome assembly and directs
PRMT5 methylation to Sm proteins
[44, 45, 47, 113, 167]
RioK1
Competes with pICln for PRMT5 binding and recruits
nucleolin for methylation
[108]
Menin/MEN1
Adapter protein for MLL methyltransferase that targets
PRMT5 to chromatin
[110–112]
CoPR5
Mammalian nuclear protein that targets PRMT5 to
chromatin
[93, 174]
hSWI/SNF Chromatin remodeling
complexes
Targets PRMT5 to chromatin and methylation
of Histone H3
[13, 57, 58, 60, 82, 84, 122, 164]
JAK kinases
Mutant Jak2 found in leukemia phosphorylates
PRMT5 and reduces its activity
[11, 117]
Blimp1
Localization of PRMT5 in primordial germ cells
[54]
AJUBA
Piwi
Coordinates PRMT5 interaction with SNAIL
Recruitment via Tudor domain proteins to piRNA
pathways
[120]
[95–97, 101]
a
Caution is warranted when considering PRMT5 interacting proteins identified in the literature by anti-FLAG precipitation (not shown here) as
PRMT5 was shown to directly interact with FLAG antibodies [175]
PTMs on PRMT5 or MEP50 also modulate methyltransferase activity. Although PRMT5 was first identified
through its interaction with Jak2 protein in humans [11], the
functional significance of this finding was not fully realized
until recently. Mutant Jak2, common in certain types of
leukemia, phosphorylates PRMT5 on its N-terminus in a
region that is highly conserved from human to Xenopus
(Y304 shown in Fig. 6c) [117]. This may abolish the interaction of PRMT5 with the histone substrate by clashing
with its N-terminal Ser1 and thus significantly impairs the
ability of PRMT5 to methylate histones H2A or H4 on R3
(similarly to H2A/H4 S1ph, Fig. 6c) [35, 117]. Conversely,
phosphorylation of MEP50 on T5 increases the methyltransferase activity of PRMT5–MEP50 toward H4 [118],
potentially by increased affinity for histone substrates. Finally, PRMT5 can influence the activity of other enzymes,
as PRMT5 methylation of the transcription factor GATA4
inhibits p300-mediated GATA4 acetylation [119].
Subcellular localization and other regulation of PRMT5
In a variety of somatic cells, PRMT5 predominantly localizes to the cytoplasm [120–122] and as noted above the
translocation of PRMT5 appears to play a role in controlling
pluripotency in early development of mouse embryos [65].
PRMT5 has three novel nuclear exclusion signals (NES)
that are unlike the conventional leucine-rich NES [123].
PRMT5 localization is also regulated by binding partners.
The transcription factor SNAIL forms a complex with
PRMT5–MEP50 mediated by the LIM protein AJUBA
[120] and promotes translocation of the primarily cytoplasmic AJUBA and PRMT5 to the nucleus. SNAIL recruits the
complex to the E-cadherin proximal promoter, resulting in
increased methylation of H4R3. PRMT5 knockdown or inhibition results in expression of E-cadherin, suggesting
transcriptional repression of E-cadherin by the SNAIL
complex is dependent on PRMT5 methyltransferase activity.
The SNAIL-induced epithelial-to-mesenchymal transition is
essential during development and a major contributor to
metastasis and tumor progression [124].
PRMT5 translation is regulated by miRNAs in mantle
cell lymphoma (MCL) cells, in which a global increase in
PRMT5 protein and H3R8 and H4R3 methylation appears
despite less mRNA and slower transcription compared to
normal B lymphocytes [122]. Re-expression of miRNAs
that normally bind the 30 UTR of PRMT5 results in a strong
decrease in PRMT5 protein levels. Similar results were
obtained in transformed B cell chronic lymphocytic leukemia (B-CLL) cell lines [57]. Intriguingly, a prmt5
antisense RNA is found embedded within the prmt5 gene
in the human genome possibly causing a similar effect on
translation (NCBI Entrez Gene ID 100505758).
PRMT5–MEP50 in cancer
PRMT5’s regulation of proliferation and its direct interaction with proteins commonly misregulated or mutated in
123
N. Stopa et al.
b Fig. 6 Structural basis for modification crosstalk regulation of
A
B
C
cancer indicate that PRMT5 may play a role in cancer as an
oncogene [21–24, 57, 123, 125–129]. Cancer etiology is
now highly correlated with alterations in the histone code
signaling of epigenetic information [130, 131]. Yang and
Bedford [132] provide an overall literature review of the
role of the family of PRMTs in cancer.
Increased expression and mutation of PRMT5 and
MEP50 are found in a wide range of cancers, as we extracted from The Cancer Genome Atlas project database
(Fig. 7a) [133]. PRMT5 overexpression appears to be an
important factor in its tumorigenicity and occurs in a large
123
PRMT5 activity. The crystal structure of PRMT5–MEP50 complexed
with H4 (1–8) tail peptide (PDB:4GQB) provided insight into activity
crosstalk by other histone PTMs. a The histone H4 Lys 5 (H4K5,
black stick) interacts with PRMT5 through a hydrogen bond between
a structural water molecule (red ball) and its e-NH2. b Modeled
interactions between an acetylated histone H4 Lys 5 (H4K5ac, yellow
stick) within the HsPRMT5 active site. The oxygen-carbonyl occupies
the position of the structural water molecule shown in a. Acetylation
of the peptide at the K5 position increases the enzyme/substrate
affinity through enhanced hydrogen bonding. c Modeled potential
interactions between a phosphorylated histone H4 Ser 1 (H4S1ph) and
the enzyme. The potential occupied space of the phosphorylated
residue is shown in mesh, and may either sterically block histone
peptide interaction, electrostatically repel PRMT5 Y304 in an active
site pH-dependent fashion, or alternatively enhance interaction with
enzyme and reduce turnover
number of cancers, including ovarian, lung, lymphoid,
lymphoma, glioblastoma multiforme, melanoma, colon,
gastric, bladder cancer and germ cell tumors [57, 122, 123,
127–129, 134–138]. In epithelial ovarian cancer, elevated
PRMT5 correlates with decreased patient survival [128].
Elevated PRMT5 and MEP50 expression in non-small cell
lung cancer (NSCLC) is highly correlated (logrank
P *2 9 10-6) with poorer survival in a large sample of
patients, as we extracted from a clinical database of published data (http://www.kmplot.com, Fig. 7b, c) [139].
Mechanistic insight into this elevated expression in lung
adenocarcinoma was shown by studies in which high cytoplasmic expression of PRMT5 was directly correlated
with poor prognosis, possibly mediated through the epithelial-to mesenchymal transition [140] and histone
methylation [141]. PRMT5 overexpression causes the formation of tumors in nude mice [135]. MEP50 had
significant parallel roles in enhancing PRMT5 methylation
of PI3-kinase to promote lung cancer tumorigenesis [142].
PRMT5 overexpression also results in increased proliferation and induced anchorage-independent colony growth
[13, 135]. Conversely, PRMT5 knockdown significantly
reduces cellular proliferation and colony formation in
breast and lung cancer cells [13, 135, 143]. PRMT5 depletion inhibits proliferation in a majority of metastatic
melanoma cell lines but accelerates growth in others [129].
These results suggest cell type might be an important factor
in determining if overexpression leads to increased growth.
However, no effect on cellular proliferation is observed
when PRMT5 is overexpressed in MCF-7 breast cancer
cells [143]. PRMT5 overexpression in cancer may in part
be mediated by the NF-Y transcription factor, known to
directly control cell cycle genes and other proliferative and
cell survival factors [144]. PRMT5-catalyzed methylation
of the growth factor receptor EGFR reduces its autophosphorylation, attenuating its activation and potentially
playing a role in tumorigenesis [145].
The PRMT5 arginine methyltransferase
A
B
C
Fig. 7 PRMT5 is altered in a range of cancers and its expression is
correlated with poor prognosis. a The alteration frequency of prmt5
gene amplification, mutation, and deletions in a wide range of human
cancers cataloged in The Cancer Genome Atlas (TCGA, accessed
through the cBio Cancer Genomics Portal; http://www.cbioportal.org)
was plotted in a histogram, ranging up to 4.5 % alteration in uterine
cancer. This analysis did not include increased gene expression or
protein abundance. b A Kaplan–Meier survival probability plot for
high (orange) versus low (gray) prmt5 gene expression/mRNA level
for lung cancer is shown, with high prmt5 expression resulting in a
*1.5-fold worse survival (hazard ratio) at very high significance. c A
Kaplan–Meier survival probability plot for high (orange) versus low
(gray) mep50 gene expression/mRNA level for lung cancer is shown,
with high prmt5 expression resulting in a *1.6-fold worse survival
(hazard ratio) at very high significance. Survival data obtained from
http://www.kmplot.com
The effect of PRMT5 overexpression on cellular proliferation suggests a role for PRMT5 in regulating cell
cycle progression. PRMT5 knockdown slows the cell cycle
in NIH3T3 cells and induces G1 arrest in 293T and MCF7
cells [135, 143]. PRMT5 overexpression increases the
protein levels of the positive regulators of G1 phase cyclin
D1, cyclin D2, cyclin E1, CDK4, and CDK6, and decreases
the protein level of the negative regulator of G1 phase Rb
protein [135]. Loss of PRMT5 leads to the increased expression of the cell cycle regulator p27Kip1 [129].
PRMT5 is also linked to the expression of the oncogenes
p53, eukaryotic translation initiation factor (eIF4E), and
microphthalmia-associated transcription factor (MITF)
[129, 143, 146]. Knockdown of PRMT5 causes a significant decrease in both p53 and eIF4E [143].
Overexpression of eIF4E, a translational regulator, results
in rapid proliferation, suppression of apoptosis, and malignant transformation [147, 148]. Expression of eIF4E
rescues short-term loss of cellular proliferation caused by
PRMT5 knockdown, consistent with eIF4E functioning as
a critical downstream effector of PRMT5 activity [140].
In the human osteosarcoma cell line U2OS, PRMT5,
Strap and p53 form a complex in response to DNA damage
[71]. DNA damage-induced apoptosis is greater
123
N. Stopa et al.
concomitant with PRMT5 knockdown, indicating that
arginine methylation is a part of the p53 response. This
apoptotic response could possibly be linked to PRMT5s
role in splicing, such as in cell cycle genes with weak 50
donor sites. One of these mRNAs is Mdm4, which senses
defects in the spliceosomal machinery and transfers the
signal to activate the p53 response [53]. Furthermore,
PRMT5 monomethylates p53 within its oligomerization
domain on a similar ‘‘GRGR/K’’ sequence to that found in
histones, modestly influencing p53 tetramer formation and
its target selection [71].
PRMT5 activity is modulated by the DAL-1/4.1B tumor
suppressor which is known to function in pro-apoptotic
pathways in breast cancer cells [149, 150] and is essential
for the growth of lung cancer cells [123, 135]. The programmed cell death 4 (PDCD4) tumor suppressor protein
conversely functions to promote cell growth and tumor
formation when overexpressed with PRMT5 [126, 151].
Menin/MEN1 interacts with PRMT5 to alter its activity,
and cancer-associated Menin mutations appear to block
this interaction, possibly altering the targeting of PRMT5
and promoting tumorigenesis [110, 111].
In developing fetal testes, both PRMT5 and MEP50
were nuclear in Leydig cells and in adult nonneoplastic
testes; in contrast, testicular cancers exhibited reduced
nuclear PRMT5 and MEP50 with enhanced cytoplasmic
localization [125]. Similarly, cytoplasmic expression of
MEP50 in prostate cancer cells promotes both androgenand estrogen-mediated transcriptional activity and tumorigenesis [17, 23], while forced nuclear localization of
MEP50 inhibited prostate cancer cell proliferation [24].
Consistently, targeting PRMT5 to the nucleus by fusing a
nuclear localization signal (NLS) to the N-terminus of
PRMT5 also results in inhibition of growth of LNCaP cells.
In contrast, MEP50 was nuclear in invasive ovarian and
breast cancer cells while mainly cytoplasmic in normal
cells [22]. Consistent with this observation, overexpression
of MEP50 in the nucleus stimulated proliferation and invasion only in the presence of estrogen or androgen [19].
Part of the role of MEP50 in hormone-responsive tumors
may be independent of PRMT5, mediated through interaction and recruitment of the Smad1 transcription factor
[16].
PRMT5 in additional diseases and future drug design
outlook
Host and microbe PRMTs are involved in infectious disease pathways. Parasitic protozoa with PRMTs have a
conserved Type I PRMT with homology to PRMT1 and a
conserved Type II PRMT with homology to PRMT5 [152].
PRMT5 also binds and methylates the Epstein–Barr
123
Nuclear Antigen protein and stimulates EBNA-dependent
transcription, possibly indicating that host PRMT5 plays a
role in latent EB infection [153, 154]. Retroviral infections
may also be regulated by PRMT5. Human T lymphotropic
viruses encode accessory proteins p30 and p28, which were
shown to interact specifically with PRMT5, while reduction of host cell PRMT5 levels decreased HTLV-2, but not
HTLV-1, viral gene expression [155]. The HIV Tat protein
is known to be methylated and regulated by PRMT6, and
contains a long stretch of ‘‘GR’’ residues, suggesting that it
may also be a target of PRMT5 [156].
PRMT5 may also have significance for heart disease.
PRMT5, along with PRMT3, was shown to bind to and
methylate the voltage-gated sodium channel NaV1.5.
Strikingly, this arginine methylation enhanced NaV1.5 cell
surface localization and current density, showing that this
regulation may be a previously unknown component of
heart health and disease [157]. PRMT5 also was shown to
interact with GATA4 in cardiomyocytes and methylated it
on three Arg residues, inhibiting the ability of GATA4 to
promote transcriptional activation [119].
A number of other arginine and lysine methyltransferases
have also been implicated in cancer and other diseases [132,
158, 159]. This makes PRMT5, and protein methyltransferases in general, a prime target for drug development and
diagnostics [159]. Though no pharmacological treatments
directly targeting PRMT5 are available yet, research into
PRMT5 inhibitors has greatly increased within the last several years, with a number of inhibitors currently being
developed specifically for application to cancer, b-thalassemia, or sickle cell disease. Interestingly, the epizyme
inhibitor EPZ004777 directed against the Dot1L lysine
methyltransferase also inhibits PRMT5, but not the PRMT5–
MEP50 complex, suggesting that some of its activity may be
due to PRMT5 inhibition [160, 161].
Concluding remarks
Mono- and symmetric dimethylation of arginine is versatile
and commonly utilized PTMs that until recently were under-recognized. An ever-greater number of proteins and
cellular pathways are now known to be regulated by these
modification states, including the splicing machinery and
histones that are the foundation of many essential biological functions. Here, we focused on PRMT5 and
highlighted its mechanisms of catalysis and substrate
recognition, the somatic and cancerous biological processes that PRMT5 and its partner MEP50 participate in or
are essential for, and showed the role PRMT5 and MEP50
play in early development. Current and forthcoming insights into PRMT5’s molecular mechanisms of targeting
specific proteins and catalyzing mono- and dimethylation
The PRMT5 arginine methyltransferase
will provide crucial information for the development of
specific small molecule inhibitors. Future research will
clarify the role of PRMT5 in development and disease,
while the development of specific small molecule inhibitors of PRMT5 may lead to novel chemotherapeutic
approaches for cancer. However, caution is necessary in
the potential use of specific PRMT5 inhibitors due to their
multiple biological roles, suggesting possible toxicity from
its inhibition. New studies targeting PRMT5, and redundancy with other methyltransferases such as PRMT7, and
their multiple biological roles are necessary to fully understand how PRMT5 functions in health and disease. New
tools, such as better methylarginine antibodies that can
distinguish histone substrates and mono- and dimethylation
states, as well as conditional knockouts in cell culture and
animals will be essential for future elucidation of the important biological roles of PRMT5.
Acknowledgments N.S. and J.K. were supported by NIH/NIGMS
[P20GM103395]. D.S. is funded by an NIH/NIGMS grant
[R01GM108646] and by The American Cancer Society—Robbie Sue
Mudd Kidney Cancer Research Scholar Grant [124891-RSG-13-39601-DMC]. We are grateful to Emmanuel Burgos for structural and
enzymatic insight and for rendering Fig. 6. The analysis shown in
Fig. 7 is based upon data generated by the TCGA Research Network:
http://cancergenome.nih.gov and from KM-plotter: http://kmplot.
com. We thank the specimen donors to these projects for their
essential contributions. We thank the many investigators studying
PRMT5 and we apologize to the authors whose work on PRMT5 was
not included due to space limitations.
References
1. Di Lorenzo A, Bedford MT (2011) Histone arginine methylation. FEBS Lett 585(13):2024–2031. doi:10.1016/j.febslet.2010.
11.010
2. Niewmierzycka A, Clarke S (1999) S-Adenosylmethionine-dependent methylation in Saccharomyces cerevisiae. Identification
of a novel protein arginine methyltransferase. J Biol Chem
274(2):814–824
3. Bedford MT, Clarke SG (2009) Protein arginine methylation in
mammals: who, what, and why. Mol Cell 33(1):1–13. doi:10.
1016/j.molcel.2008.12.013
4. Migliori V, Muller J, Phalke S, Low D, Bezzi M, Mok WC,
Sahu SK, Gunaratne J, Capasso P, Bassi C, Cecatiello V, De
Marco A, Blackstock W, Kuznetsov V, Amati B, Mapelli M,
Guccione E (2012) Symmetric dimethylation of H3R2 is a
newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol 19(2):136–144. doi:10.1038/nsmb.
2209
5. Zurita-Lopez CI, Sandberg T, Kelly R, Clarke SG (2012) Human protein arginine methyltransferase 7 (PRMT7) is a type III
enzyme forming omega-NG-monomethylated arginine residues.
J Biol Chem 287(11):7859–7870. doi:10.1074/jbc.M111.336271
6. Feng Y, Maity R, Whitelegge JP, Hadjikyriacou A, Li Z, ZuritaLopez C, Al-Hadid Q, Clark AT, Bedford MT, Masson JY,
Clarke SG (2013) Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and
arginine-rich regions. J Biol Chem 288(52):37010–37025.
doi:10.1074/jbc.M113.525345
7. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS,
Chaerkady R, Madugundu AK, Kelkar DS, Isserlin R, Jain S,
Thomas JK, Muthusamy B, Leal-Rojas P, Kumar P, Sahasrabuddhe NA, Balakrishnan L, Advani J, George B, Renuse
S, Selvan LD, Patil AH, Nanjappa V, Radhakrishnan A, Prasad
S, Subbannayya T, Raju R, Kumar M, Sreenivasamurthy SK,
Marimuthu A, Sathe GJ, Chavan S, Datta KK, Subbannayya Y,
Sahu A, Yelamanchi SD, Jayaram S, Rajagopalan P, Sharma J,
Murthy KR, Syed N, Goel R, Khan AA, Ahmad S, Dey G,
Mudgal K, Chatterjee A, Huang TC, Zhong J, Wu X, Shaw PG,
Freed D, Zahari MS, Mukherjee KK, Shankar S, Mahadevan A,
Lam H, Mitchell CJ, Shankar SK, Satishchandra P, Schroeder
JT, Sirdeshmukh R, Maitra A, Leach SD, Drake CG, Halushka
MK, Prasad TS, Hruban RH, Kerr CL, Bader GD, IacobuzioDonahue CA, Gowda H, Pandey A (2014) A draft map of the
human proteome. Nature 509(7502):575–581. doi:10.1038/
nature13302
8. Cook JR, Lee JH, Yang ZH, Krause CD, Herth N, Hoffmann R,
Pestka S (2006) FBXO11/PRMT9, a new protein arginine
methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Commun 342(2):472–481. doi:10.
1016/j.bbrc.2006.01.167
9. Ma XJ, Lu Q, Grunstein M (1996) A search for proteins that
interact genetically with histone H3 and H4 amino termini uncovers novel regulators of the Swe1 kinase in Saccharomyces
cerevisiae. Genes Dev 10(11):1327–1340
10. Gilbreth M, Yang P, Bartholomeusz G, Pimental RA, Kansra S,
Gadiraju R, Marcus S (1998) Negative regulation of mitosis in
fission yeast by the shk1 interacting protein skb1 and its human
homolog,
Skb1Hs.
Proc
Natl
Acad
Sci
USA
95(25):14781–14786
11. Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL,
Pestka S (1999) The human homologue of the yeast proteins
Skb1 and Hsl7p interacts with Jak kinases and contains protein
methyltransferase activity. J Biol Chem 274(44):31531–31542
12. Branscombe TL, Frankel A, Lee JH, Cook JR, Yang Z, Pestka S,
Clarke S (2001) PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in
proteins. J Biol Chem 276(35):32971–32976. doi:10.1074/jbc.
M105412200
13. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S
(2004) Human SWI/SNF-associated PRMT5 methylates histone
H3 arginine 8 and negatively regulates expression of ST7 and
NM23
tumor
suppressor
genes.
Mol
Cell
Biol
24(21):9630–9645. doi:10.1128/mcb.24.21.9630-9645.2004
14. Jahan S, Davie JR (2014) Protein arginine methyltransferases
(PRMTs): role in chromatin organization. Adv Biol Regul.
doi:10.1016/j.jbior.2014.09.003
15. Zhou L, Hosohata K, Gao S, Gu Z, Wang Z (2013) cGMPdependent protein kinase Ibeta interacts with p44/WDR77 to
regulate androgen receptor-driven gene expression. PLoS ONE
8(6):e63119. doi:10.1371/journal.pone.0063119
16. Li Y, Tian L, Ligr M, Daniels G, Peng Y, Wu X, Singh M, Wei
J, Shao Y, Lepor H, Xu R, Chang Z, Wang Z, Lee P (2013)
Functional domains of androgen receptor coactivator p44/
Mep50/WDR77 and its interaction with Smad1. PLoS ONE
8(5):e64663. doi:10.1371/journal.pone.0064663
17. Gao S, Wang Z (2012) Subcellular localization of p44/WDR77
determines proliferation and differentiation of prostate epithelial
cells. PLoS ONE 7(11):e49173. doi:10.1371/journal.pone.
0049173
18. Vincent B, Wu H, Gao S, Wang Z (2012) Loss of the androgen
receptor cofactor p44/WDR77 induces astrogliosis. Mol Cell
Biol 32(17):3500–3512. doi:10.1128/mcb.00298-12
19. Ligr M, Patwa RR, Daniels G, Pan L, Wu X, Li Y, Tian L,
Wang Z, Xu R, Wu J, Chen F, Liu J, Wei JJ, Lee P (2011)
123
N. Stopa et al.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Expression and function of androgen receptor coactivator p44/
Mep50/WDR77 in ovarian cancer. PLoS ONE 6(10):e26250.
doi:10.1371/journal.pone.0026250
Gu Z, Zhou L, Gao S, Wang Z (2011) Nuclear transport signals
control cellular localization and function of androgen receptor
cofactor p44/WDR77. PLoS ONE 6(7):e22395. doi:10.1371/
journal.pone.0022395
Gao S, Wu H, Wang F, Wang Z (2010) Altered differentiation
and proliferation of prostate epithelium in mice lacking the
androgen receptor cofactor p44/WDR77. Endocrinology
151(8):3941–3953. doi:10.1210/en.2009-1080
Peng Y, Li Y, Gellert LL, Zou X, Wang J, Singh B, Xu R,
Chiriboga L, Daniels G, Pan R, Zhang DY, Garabedian MJ,
Schneider RJ, Wang Z, Lee P (2010) Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell
Mol Med 14(12):2780–2789. doi:10.1111/j.1582-4934.2009.
00936.x
Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X,
McLeod M, Li Y, Li CX, Feng A, Garabedian MJ, Wang Z,
Roeder RG, Lee P (2008) Distinct nuclear and cytoplasmic
functions of androgen receptor cofactor p44 and association with
androgen-independent prostate cancer. Proc Natl Acad Sci USA
105(13):5236–5241. doi:10.1073/pnas.0712262105
Zhou L, Wu H, Lee P, Wang Z (2006) Roles of the androgen
receptor cofactor p44 in the growth of prostate epithelial cells.
J Mol Endocrinol 37(2):283–300. doi:10.1677/jme.1.02062
Schapira M, Ferreira de Freitas R (2014) Structural biology and
chemistry of protein arginine methyltransferases. MedChemComm. doi:10.1039/C4MD00269E
Sun L, Wang M, Lv Z, Yang N, Liu Y, Bao S, Gong W, Xu RM
(2011) Structural insights into protein arginine symmetric
dimethylation by PRMT5. Proc Natl Acad Sci USA
108(51):20538–20543. doi:10.1073/pnas.1106946108
Zhang X, Cheng X (2003) Structure of the predominant protein
arginine methyltransferase PRMT1 and analysis of its binding to
substrate
peptides.
Structure 11(5):509–520
pii:
S0969212603000716
Zhang X, Zhou L, Cheng X (2000) Crystal structure of the
conserved core of protein arginine methyltransferase PRMT3.
EMBO J 19(14):3509–3519. doi:10.1093/emboj/19.14.3509
Yue WW, Hassler M, Roe SM, Thompson-Vale V, Pearl LH
(2007) Insights into histone code syntax from structural and
biochemical studies of CARM1 methyltransferase. EMBO J
26(20):4402–4412. doi:10.1038/sj.emboj.7601856
Troffer-Charlier N, Cura V, Hassenboehler P, Moras D,
Cavarelli J (2007) Functional insights from structures of coactivator-associated arginine methyltransferase 1 domains. EMBO
J 26(20):4391–4401. doi:10.1038/sj.emboj.7601855
Cheng Y, Frazier M, Lu F, Cao X, Redinbo MR (2011) Crystal
structure of the plant epigenetic protein arginine methyltransferase 10. J Mol Biol 414(1):106–122. doi:10.1016/j.jmb.2011.
09.040
Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, Wasney GA, Chau I, Marcellus R, Hajian T, Liu F,
Korboukh I, Smil D, Bolshan Y, Min J, Wu H, Zeng H, Loppnau
P, Poda G, Griffin C, Aman A, Brown PJ, Jin J, Al-Awar R,
Arrowsmith CH, Schapira M, Vedadi M (2012) An allosteric
inhibitor of protein arginine methyltransferase 3. Structure 20(8):1425–1435. doi:10.1016/j.str.2012.06.001
Wang C, Zhu Y, Chen J, Li X, Peng J, Chen J, Zou Y, Zhang Z,
Jin H, Yang P, Wu J, Niu L, Gong Q, Teng M, Shi Y (2014)
Crystal structure of arginine methyltransferase 6 from Trypanosoma brucei. PLoS ONE 9(2):e87267. doi:10.1371/journal.
pone.0087267
Ho M-C, Wilczek C, Bonanno JB, Xing L, Seznec J, Matsui T,
Carter LG, Onikubo T, Kumar PR, Chan MK, Brenowitz M,
123
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
Cheng RH, Reimer U, Almo SC, Shechter D (2013) Structure of
the arginine methyltransferase PRMT5–MEP50 reveals a
mechanism for substrate specificity. PLoS ONE 8(2):e57008.
doi:10.1371/journal.pone.0057008
Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z,
Gheyi T, Han B, Jungheim LN, Qian Y, Rauch C, Russell M,
Sauder JM, Wasserman SR, Weichert K, Willard FS, Zhang A,
Emtage S (2012) Crystal structure of the human PRMT5:MEP50
complex. Proc Natl Acad Sci USA 109(44):17960–17965.
doi:10.1073/pnas.1209814109
Furuno K, Masatsugu T, Sonoda M, Sasazuki T, Yamamoto K
(2006) Association of Polycomb group SUZ12 with WD-repeat
protein MEP50 that binds to histone H2A selectively in vitro.
Biochem Biophys Res Commun 345(3):1051–1058. doi:10.
1016/j.bbrc.2006.05.014
Wilczek C, Chitta R, Woo E, Shabanowitz J, Chait BT, Hunt
DF, Shechter D (2011) Protein arginine methyltransferase
Prmt5–Mep50 methylates histones H2A and H4 and the histone
chaperone nucleoplasmin in Xenopus laevis eggs. J Biol Chem
286(49):42221–42231. doi:10.1074/jbc.M111.303677
Wang M, Xu RM, Thompson PR (2013) Substrate specificity,
processivity, and kinetic mechanism of protein arginine
methyltransferase 5. Biochemistry 52(32):5430–5440. doi:10.
1021/bi4005123
Osborne TC, Obianyo O, Zhang X, Cheng X, Thompson PR
(2007) Protein arginine methyltransferase 1: positively charged
residues in substrate peptides distal to the site of methylation are
important for substrate binding and catalysis. Biochemistry
46(46):13370–13381. doi:10.1021/bi701558t
Gui S, Gathiaka S, Li J, Qu J, Acevedo O, Hevel JM (2014) A
remodeled protein arginine methyltransferase 1 (PRMT1) generates
symmetric
dimethylarginine.
J
Biol
Chem
289(13):9320–9327. doi:10.1074/jbc.M113.535278
Gonsalvez GB, Tian L, Ospina JK, Boisvert FM, Lamond AI,
Matera AG (2007) Two distinct arginine methyltransferases are
required for biogenesis of Sm-class ribonucleoproteins. J Cell
Biol 178(5):733–740. doi:10.1083/jcb.200702147
Brahms H, Meheus L, de Brabandere V, Fischer U, Luhrmann R
(2001) Symmetrical dimethylation of arginine residues in
spliceosomal Sm protein B/B0 and the Sm-like protein LSm4, and
their interaction with the SMN protein. RNA 7(11):1531–1542
Friesen WJ, Massenet S, Paushkin S, Wyce A, Dreyfuss G
(2001) SMN, the product of the spinal muscular atrophy gene,
binds preferentially to dimethylarginine-containing protein targets.
Mol
Cell
7(5):1111–1117.
doi:10.1016/S10972765(01)00244-1
Meister G, Eggert C, Buhler D, Brahms H, Kambach C, Fischer
U (2001) Methylation of Sm proteins by a complex containing
PRMT5 and the putative U snRNP assembly factor pICln. Curr
Biol 11(24):1990–1994
Friesen WJ, Paushkin S, Wyce A, Massenet S, Pesiridis GS, Van
Duyne G, Rappsilber J, Mann M, Dreyfuss G (2001) The
methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol
21(24):8289–8300. doi:10.1128/mcb.21.24.8289-8300.2001
Chari A, Golas MM, Klingenhager M, Neuenkirchen N, Sander
B, Englbrecht C, Sickmann A, Stark H, Fischer U (2008) An
assembly chaperone collaborates with the SMN complex to
generate spliceosomal SnRNPs. Cell 135(3):497–509. doi:10.
1016/j.cell.2008.09.020
Grimm C, Chari A, Pelz JP, Kuper J, Kisker C, Diederichs K,
Stark H, Schindelin H, Fischer U (2013) Structural basis of
assembly chaperone-mediated snRNP formation. Mol Cell
49(4):692–703. doi:10.1016/j.molcel.2012.12.009
Meister G, Buhler D, Pillai R, Lottspeich F, Fischer U (2001) A
multiprotein complex mediates the ATP-dependent assembly of
The PRMT5 arginine methyltransferase
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
spliceosomal U snRNPs. Nat Cell Biol 3(11):945–949. doi:10.
1038/ncb1101-945
Meister G, Fischer U (2002) Assisted RNP assembly: SMN and
PRMT5 complexes cooperate in the formation of spliceosomal
UsnRNPs. EMBO J 21(21):5853–5863
Gubitz AK, Feng W, Dreyfuss G (2004) The SMN complex.
Exp Cell Res 296(1):51–56. doi:10.1016/j.yexcr.2004.03.022
Pellizzoni L, Yong J, Dreyfuss G (2002) Essential role for the
SMN complex in the specificity of snRNP assembly. Science
298(5599):1775–1779. doi:10.1126/science.1074962
Raker VA, Plessel G, Luhrmann R (1996) The snRNP core
assembly pathway: identification of stable core protein
heteromeric complexes and an snRNP subcore particle in vitro.
EMBO J 15(9):2256–2269
Bezzi M, Teo SX, Muller J, Mok WC, Sahu SK, Vardy LA,
Bonday ZQ, Guccione E (2013) Regulation of constitutive and
alternative splicing by PRMT5 reveals a role for Mdm4 premRNA in sensing defects in the spliceosomal machinery. Genes
Dev 27(17):1903–1916. doi:10.1101/gad.219899.113
Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ,
Kouzarides T, Surani MA (2006) Blimp1 associates with Prmt5
and directs histone arginine methylation in mouse germ cells.
Nat Cell Biol 8(6):623–630. doi:10.1038/ncb1413
Bedford MT (2007) Arginine methylation at a glance. J Cell Sci
120(Pt 24):4243–4246. doi:10.1242/jcs.019885
Xu X, Hoang S, Mayo MW, Bekiranov S (2010) Application of
machine learning methods to histone methylation ChIP-Seq data
reveals H4R3me2 globally represses gene expression. BMC
Bioinform 11:396. doi:10.1186/1471-2105-11-396
Wang L, Pal S, Sif S (2008) Protein arginine methyltransferase 5
suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol
28(20):6262–6277. doi:10.1128/mcb.00923-08
Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J,
Tempst P, Sif S (2003) mSin3A/histone deacetylase 2- and PRMT5containing Brg1 complex is involved in transcriptional repression of
the Myc target gene cad. Mol Cell Biol 23(21):7475–7487
Fabbrizio E, El Messaoudi S, Polanowska J, Paul C, Cook JR,
Lee JH, Negre V, Rousset M, Pestka S, Le Cam A, Sardet C
(2002) Negative regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO Rep 3(7):641–645.
doi:10.1093/embo-reports/kvf136
Seth-Vollenweider T, Joshi S, Dhawan P, Sif S, Christakos S
(2014) Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3 induced CYP24A1 transcription: epigenetic
modification involving crosstalk between protein arginine
methyltransferase 5 and the SWI/SNF complex. J Biol Chem.
doi:10.1074/jbc.M114.583302
Majumder S, Alinari L, Roy S, Miller T, Datta J, Sif S, Baiocchi
R, Jacob ST (2010) Methylation of histone H3 and H4 by
PRMT5 regulates ribosomal RNA gene transcription. J Cell
Biochem 109(3):553–563. doi:10.1002/jcb.22432
Yue M, Li Q, Zhang Y, Zhao Y, Zhang Z, Bao S (2013) Histone
H4R3 methylation catalyzed by SKB1/PRMT5 is required for
maintaining shoot apical meristem. PLoS ONE 8(12):e83258.
doi:10.1371/journal.pone.0083258
Wang X, Zhang Y, Ma Q, Zhang Z, Xue Y, Bao S, Chong K
(2007) SKB1-mediated symmetric dimethylation of histone
H4R3 controls flowering time in Arabidopsis. EMBO J
26(7):1934–1941. doi:10.1038/sj.emboj.7601647
Tsutsui T, Fukasawa R, Shinmyouzu K, Nakagawa R, Tobe K,
Tanaka A, Ohkuma Y (2013) Mediator complex recruits epigenetic regulators via its two cyclin-dependent kinase subunits
to repress transcription of immune response genes. J Biol Chem
288(29):20955–20965. doi:10.1074/jbc.M113.486746
65. Tee WW, Pardo M, Theunissen TW, Yu L, Choudhary JS,
Hajkova P, Surani MA (2010) Prmt5 is essential for early mouse
development and acts in the cytoplasm to maintain ES cell
pluripotency. Genes Dev 24(24):2772–2777. doi:10.1101/gad.
606110
66. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z,
Wei G, Chepelev I, Zhao K (2007) High-resolution profiling of
histone methylations in the human genome. Cell
129(4):823–837
67. Girardot M, Hirasawa R, Kacem S, Fritsch L, Pontis J, Kota SK,
Filipponi D, Fabbrizio E, Sardet C, Lohmann F, Kadam S, AitSi-Ali S, Feil R (2014) PRMT5-mediated histone H4 arginine-3
symmetrical dimethylation marks chromatin at G ? C-rich regions of the mouse genome. Nucleic Acids Res 42(1):235–248.
doi:10.1093/nar/gkt884
68. Capurso D, Xiong H, Segal MR (2012) A histone arginine
methylation localizes to nucleosomes in satellite II and III DNA
sequences in the human genome. BMC Genom 13:630. doi:10.
1186/1471-2164-13-630
69. Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE (2014) Tumor necrosis factor (TNF)-alpha induction of
CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-kappaB
p65 methylation. J Biol Chem 289(22):15328–15339. doi:10.
1074/jbc.M114.547349
70. Wei H, Wang B, Miyagi M, She Y, Gopalan B, Huang DB,
Ghosh G, Stark GR, Lu T (2013) PRMT5 dimethylates R30 of
the p65 subunit to activate NF-kappaB. Proc Natl Acad Sci USA
110(33):13516–13521. doi:10.1073/pnas.1311784110
71. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M,
Kessler B, La Thangue NB (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10(12):1431–1439.
doi:10.1038/ncb1802
72. Zheng S, Moehlenbrink J, Lu YC, Zalmas LP, Sagum CA, Carr
S, McGouran JF, Alexander L, Fedorov O, Munro S, Kessler B,
Bedford MT, Yu Q, La Thangue NB (2013) Arginine methylation-dependent reader-writer interplay governs growth control
by E2F-1. Mol Cell 52(1):37–51. doi:10.1016/j.molcel.2013.08.
039
73. Gayatri S, Bedford MT (2014) Readers of histone methylarginine marks. Biochim Biophys Acta 1839(8):702–710.
doi:10.1016/j.bbagrm.2014.02.015
74. Côté J, Richard S (2005) Tudor domains bind symmetrical
dimethylated arginines. J Biol Chem 280(31):28476–28483.
doi:10.1074/jbc.M414328200
75. Liu K, Chen C, Guo Y, Lam R, Bian C, Xu C, Zhao DY, Jin J,
MacKenzie F, Pawson T, Min J (2010) Structural basis for
recognition of arginine methylated Piwi proteins by the extended Tudor domain. Proc Natl Acad Sci USA
107(43):18398–18403. doi:10.1073/pnas.1013106107
76. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti
L, Curtis DJ, Patel DJ, Allis CD, Cunningham JM, Jane SM
(2009) PRMT5-mediated methylation of histone H4R3 recruits
DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 16(3):304–311. doi:10.1038/nsmb.
1568
77. Rank G, Cerruti L, Simpson RJ, Moritz RL, Jane SM, Zhao Q
(2010) Identification of a PRMT5-dependent repressor complex
linked to silencing of human fetal globin gene expression. Blood
116(9):1585–1592. doi:10.1182/blood-2009-10-251116
78. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M (2009) Structural basis for recognition of H3K4
methylation status by the DNA methyltransferase 3A ATRXDNMT3-DNMT3L domain. EMBO Rep 10(11):1235–1241.
doi:10.1038/embor.2009.218
123
N. Stopa et al.
79. Li J, Zhou F, Zhan D, Gao Q, Cui N, Li J, Iakhiaeva E, Zwieb C,
Lin B, Wong J (2012) A novel histone H4 arginine 3 methylation-sensitive histone H4 binding activity and transcriptional
regulatory function for signal recognition particle subunits
SRP68 and SRP72. J Biol Chem 287(48):40641–40651. doi:10.
1074/jbc.M112.414284
80. Yuan C-C, Matthews Adam GW, Jin Y, Chen Chang F, Chapman Brad A, Ohsumi Toshiro K, Glass Karen C, Kutateladze
Tatiana G, Borowsky Mark L, Struhl K, Oettinger Marjorie A
(2012) Histone H3R2 symmetric dimethylation and histone
H3K4 trimethylation are tightly correlated in eukaryotic genomes. Cell Reports 1(2):83–90
81. Karkhanis V, Hu Y-J, Baiocchi RA, Imbalzano AN, Sif S (2011)
Versatility of PRMT5-induced methylation in growth control
and development. Trends Biochem Sci 36(12):633–641. doi:10.
1016/j.tibs.2011.09.001
82. Dacwag CS, Ohkawa Y, Pal S, Sif S, Imbalzano AN (2007) The
protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin
remodeling. Mol Cell Biol 27(1):384–394. doi:10.1128/mcb.
01528-06
83. Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers
WA, Cohen A, Lasonder E, Stunnenberg HG (2006) MBD2/
NuRD and MBD3/NuRD, two distinct complexes with different
biochemical and functional properties. Mol Cell Biol
26(3):843–851. doi:10.1128/mcb.26.3.843-851.2006
84. Dacwag CS, Bedford MT, Sif S, Imbalzano AN (2009) Distinct
protein arginine methyltransferases promote ATP-dependent
chromatin remodeling function at different stages of skeletal
muscle differentiation. Mol Cell Biol 29(7):1909–1921. doi:10.
1128/mcb.00742-08
85. Mallappa C, Hu YJ, Shamulailatpam P, Tae S, Sif S, Imbalzano
AN (2011) The expression of myogenic microRNAs indirectly
requires protein arginine methyltransferase (Prmt)5 but directly
requires Prmt4. Nucleic Acids Res 39(4):1243–1255. doi:10.
1093/nar/gkq896
86. Gkountela S, Li Z, Chin CJ, Lee SA, Clark AT (2014) PRMT5 is
required for human embryonic stem cell proliferation but not
pluripotency. Stem cell Rev 10(2):230–239. doi:10.1007/
s12015-013-9490-z
87. Nicklay JJ, Shechter D, Chitta RK, Garcia BA, Shabanowitz J,
Allis CD, Hunt DF (2009) Analysis of histones in Xenopus
laevis. II. Mass spectrometry reveals an index of cell typespecific modifications on H3 and H4. J Biol Chem
284(2):1075–1085. doi:10.1074/jbc.M807274200
88. Shechter D, Nicklay JJ, Chitta RK, Shabanowitz J, Hunt DF,
Allis CD (2009) Analysis of histones in Xenopus laevis. I. A
distinct index of enriched variants and modifications exists in
each cell type and is remodeled during developmental transitions. J Biol Chem 284(2):1064–1074. doi:10.1074/jbc.
M807273200
89. Wang WL, Anderson LC, Nicklay JJ, Chen H, Gamble MJ,
Shabanowitz J, Hunt DF, Shechter D (2014) Phosphorylation
and arginine methylation mark histone H2A prior to deposition
during Xenopus laevis development. Epigenetics Chromatin
7:22. doi:10.1186/1756-8935-7-22
90. Chittka A, Nitarska J, Grazini U, Richardson WD (2012)
Transcription factor positive regulatory domain 4 (PRDM4)
recruits protein arginine methyltransferase 5 (PRMT5) to mediate histone arginine methylation and control neural stem cell
proliferation
and
differentiation.
J
Biol
Chem
287(51):42995–43006. doi:10.1074/jbc.M112.392746
91. Huang J, Vogel G, Yu Z, Almazan G, Richard S (2011) Type II
arginine methyltransferase PRMT5 regulates the gene expression of inhibitors of differentiation/DNA binding ID2 and ID4
123
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
during glial cell differentiation. J Biol Chem 286:44429–44432.
doi:10.1074/jbc.M111.277046
Kanade SR, Eckert RL (2012) Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cdeltaand p38delta-dependent signaling and keratinocyte differentiation. J Biol Chem 287(10):7313–7323. doi:10.1074/jbc.M111.
331660
Paul C, Sardet C, Fabbrizio E (2012) The histone- and PRMT5associated protein COPR5 is required for myogenic differentiation. Cell Death Differ 19(5):900–908. doi:10.1038/cdd.2011.
193
Batut J, Duboe C, Vandel L (2011) The methyltransferases
PRMT4/CARM1 and PRMT5 control differentially myogenesis
in zebrafish. PLoS ONE 6(10):e25427. doi:10.1371/journal.
pone.0025427
Kirino Y, Vourekas A, Sayed N, de Lima Alves F, Thomson T,
Lasko P, Rappsilber J, Jongens TA, Mourelatos Z (2010)
Arginine methylation of Aubergine mediates Tudor binding and
germ plasm localization. RNA 16(1):70–78. doi:10.1261/rna.
1869710
Nishida KM, Okada TN, Kawamura T, Mituyama T, Kawamura
Y, Inagaki S, Huang H, Chen D, Kodama T, Siomi H, Siomi MC
(2009) Functional involvement of Tudor and dPRMT5 in the
piRNA processing pathway in Drosophila germlines. EMBO J
28(24):3820–3831. doi:10.1038/emboj.2009.365
Kirino Y, Kim N, de Planell-Saguer M, Khandros E, Chiorean S,
Klein PS, Rigoutsos I, Jongens TA, Mourelatos Z (2009)
Arginine methylation of Piwi proteins catalysed by dPRMT5 is
required for Ago3 and Aub stability. Nat Cell Biol
11(5):652–658. doi:10.1038/ncb1872
Vagin VV, Wohlschlegel J, Qu J, Jonsson Z, Huang X, Chuma
S, Girard A, Sachidanandam R, Hannon GJ, Aravin AA (2009)
Proteomic analysis of murine Piwi proteins reveals a role for
arginine methylation in specifying interaction with Tudor family
members. Genes Dev 23(15):1749–1762. doi:10.1101/gad.
1814809
Reuter M, Chuma S, Tanaka T, Franz T, Stark A, Pillai RS
(2009) Loss of the Mili-interacting Tudor domain-containing
protein-1 activates transposons and alters the Mili-associated
small RNA profile. Nat Struct Mol Biol 16(6):639–646. doi:10.
1038/nsmb.1615
Aravin AA, Hannon GJ, Brennecke J (2007) The Piwi–piRNA
pathway provides an adaptive defense in the transposon arms
race. Science 318(5851):761–764. doi:10.1126/science.1146484
Siomi MC, Mannen T, Siomi H (2010) How does the royal
family of Tudor rule the PIWI-interacting RNA pathway? Genes
Dev 24(7):636–646. doi:10.1101/gad.1899210
Kirino Y, Vourekas A, Kim N, de Lima Alves F, Rappsilber J,
Klein PS, Jongens TA, Mourelatos Z (2010) Arginine methylation of vasa protein is conserved across phyla. J Biol Chem
285(11):8148–8154. doi:10.1074/jbc.M109.089821
Kim S, Günesdogan U, Zylicz Jan J, Hackett Jamie A, Cougot
D, Bao S, Lee C, Dietmann S, Allen George E, Sengupta R,
Surani MA (2014) PRMT5 protects genomic integrity during
global DNA demethylation in primordial germ cells and
preimplantation embryos. Mol Cell. doi:10.1016/j.molcel.2014.
10.003
Ohinata Y, Payer B, O’Carroll D, Ancelin K, Ono Y, Sano M,
Barton SC, Obukhanych T, Nussenzweig M, Tarakhovsky A,
Saitou M, Surani MA (2005) Blimp1 is a critical determinant of
the germ cell lineage in mice. Nature 436(7048):207–213.
doi:10.1038/nature03813
Durcova-Hills G, Tang F, Doody G, Tooze R, Surani MA (2008)
Reprogramming primordial germ cells into pluripotent stem cells.
PLoS ONE 3(10):e3531. doi:10.1371/journal.pone.0003531
The PRMT5 arginine methyltransferase
106. Hayashi K, de Sousa Lopes SM, Surani MA (2007) Germ cell
specification in mice. Science 316(5823):394–396. doi:10.1126/
science.1137545
107. Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo
A, Richard S, Comb MJ, Guo A, Clarke SG, Bedford MT (2013)
Loss of the major Type I arginine methyltransferase PRMT1
causes substrate scavenging by other PRMTs. Sci Rep 3:1311.
doi:10.1038/srep01311
108. Guderian G, Peter C, Wiesner J, Sickmann A, Schulze-Osthoff
K, Fischer U, Grimmler M (2011) RioK1, a new interactor of
protein arginine methyltransferase 5 (PRMT5), competes with
pICln for binding and modulates PRMT5 complex composition
and substrate specificity. J Biol Chem 286(3):1976–1986.
doi:10.1074/jbc.M110.148486
109. Teng Y, Girvan AC, Casson LK, Pierce WM Jr, Qian M, Thomas SD, Bates PJ (2007) AS1411 alters the localization of a
complex containing protein arginine methyltransferase 5 and
nucleolin. Cancer Res 67(21):10491–10500. doi:10.1158/00085472.can-06-4206
110. Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng
JM, Curran T, Hua X (2013) Menin epigenetically represses
Hedgehog signaling in MEN1 tumor syndrome. Cancer Res
73(8):2650–2658. doi:10.1158/0008-5472.can-12-3158
111. Gurung B, Hua X (2013) Menin/PRMT5/hedgehog signaling: a
potential target for the treatment of multiple endocrine neoplasia
type 1 tumors. Epigenomics 5(5):469–471. doi:10.2217/epi.13.
47
112. Gurung B, Feng Z, Hua X (2013) Menin directly represses Gli1
expression independent of canonical Hedgehog signaling. Mol
Cancer Res 11(10):1215–1222. doi:10.1158/1541-7786.mcr-130170
113. Pesiridis GS, Diamond E, Van Duyne GD (2009) Role of pICLn
in methylation of Sm proteins by PRMT5. J Biol Chem
284(32):21347–21359. doi:10.1074/jbc.M109.015578
114. Lacroix M, El Messaoudi S, Rodier G, Le Cam A, Sardet C,
Fabbrizio E (2008) The histone-binding protein COPR5 is required
for nuclear functions of the protein arginine methyltransferase
PRMT5. EMBO Rep 9(5):452–458. doi:10.1038/embor.2008.45
115. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS,
Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler
M, Harte RA, Heitner S, Hinrichs AS, Learned K, Lee BT, Li
CH, Raney BJ, Rhead B, Rosenbloom KR, Sloan CA, Speir ML,
Zweig AS, Haussler D, Kuhn RM, Kent WJ (2014) The UCSC
Genome Browser database: 2014 update. Nucleic Acids Res
42(D1):D764–D770. doi:10.1093/nar/gkt1168
116. Feng Y, Wang J, Asher S, Hoang L, Guardiani C, Ivanov I,
Zheng YG (2011) Histone H4 acetylation differentially modulates arginine methylation by an in cis mechanism. J Biol
Chem 286(23):20323–20334. doi:10.1074/jbc.M110.207258
117. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O,
Harr MW, Levine RL, Xu H, Tefferi A, Deblasio A, Hatlen M,
Menendez S, Nimer SD (2011) JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase
activity and promotes myeloproliferation. Cancer Cell
19(2):283–294. doi:10.1016/j.ccr.2010.12.020
118. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, Diehl JA
(2010) Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the
PRMT5 methyltransferase. Cancer Cell 18(4):329–340. doi:10.
1016/j.ccr.2010.08.012
119. Chen M, Yi B, Sun J (2014) Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5. J Biol Chem
289(35):24325–24335. doi:10.1074/jbc.M114.577494
120. Hou Z, Peng H, Ayyanathan K, Yan KP, Langer EM, Longmore
GD, Rauscher FJ 3rd (2008) The LIM protein AJUBA recruits
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
protein arginine methyltransferase 5 to mediate SNAIL-dependent
transcriptional
repression.
Mol
Cell
Biol
28(10):3198–3207. doi:10.1128/mcb.01435-07
Rho J, Choi S, Seong YR, Cho WK, Kim SH, Im DS (2001)
Prmt5, which forms distinct homo-oligomers, is a member of the
protein-arginine methyltransferase family. J Biol Chem
276(14):11393–11401. doi:10.1074/jbc.M008660200
Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, Sif S
(2007) Low levels of miR-92b/96 induce PRMT5 translation
and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO
J 26(15):3558–3569. doi:10.1038/sj.emboj.7601794
Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE, Wang Z
(2012) Protein arginine methyltransferase 5 is essential for
growth of lung cancer cells. Biochem J 446(2):235–241. doi:10.
1042/bj20120768
Barrallo-Gimeno A, Nieto MA (2005) The Snail genes as inducers of cell movement and survival: implications in
development and cancer. Development 132(14):3151–3161.
doi:10.1242/dev.01907
Liang JJ, Wang Z, Chiriboga L, Greco MA, Shapiro E, Huang
H, Yang XJ, Huang J, Peng Y, Melamed J, Garabedian MJ, Lee
P (2007) The expression and function of androgen receptor
coactivator p44 and protein arginine methyltransferase 5 in the
developing
testis
and
testicular
tumors.
J
Urol
177(5):1918–1922. doi:10.1016/j.juro.2007.01.017
Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS (2011)
Protein arginine methyltransferase 5 accelerates tumor growth
by arginine methylation of the tumor suppressor programmed
cell death 4. Cancer Res 71(16):5579–5587. doi:10.1158/00085472.can-11-0458
Eckert D, Biermann K, Nettersheim D, Gillis AJ, Steger K, Jack
HM, Muller AM, Looijenga LH, Schorle H (2008) Expression of
BLIMP1/PRMT5 and concurrent histone H2A/H4 arginine 3
dimethylation in fetal germ cells, CIS/IGCNU and germ cell
tumors. BMC Dev Biol 8:106. doi:10.1186/1471-213x-8-106
Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X (2013) Overexpression of PRMT5 promotes tumor cell growth and is
associated with poor disease prognosis in epithelial ovarian
cancer. J Histochem Cytochem 61(3):206–217. doi:10.1369/
0022155413475452
Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F,
Sif S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski
GB (2013) PRMT5 is upregulated in malignant and metastatic
melanoma and regulates expression of MITF and p27(Kip1.).
PLoS ONE 8(9):e74710. doi:10.1371/journal.pone.0074710
Chi P, Allis CD, Wang GG (2010) Covalent histone modifications–miswritten, misinterpreted and mis-erased in human
cancers. Nat Rev Cancer 10(7):457–469. doi:10.1038/nrc2876
Sawan C, Herceg Z (2010) Histone modifications and cancer.
Adv Genet 70:57–85. doi:10.1016/b978-0-12-380866-0.60003-4
Yang Y, Bedford MT (2013) Protein arginine methyltransferases
and cancer. Nat Rev Cancer 13(1):37–50. doi:10.1038/nrc3409
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer
SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander
C, Schultz N (2013) Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Science
Signal 6(269):pl1. doi:10.1126/scisignal.2004088
Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song
KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS (2005)
Identification of gastric cancer-related genes using a cDNA
microarray containing novel expressed sequence tags expressed
in gastric cancer cells. Clin Cancer Res 11(2 Pt 1):473–482
Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC, Chou HY, Chen JM,
Wu YC, Chiu SC, Hsu CP, Liu KL, Yu CT (2012) Protein
arginine methyltransferase 5 is a potential oncoprotein that
upregulates G1 cyclins/cyclin-dependent kinases and the
123
N. Stopa et al.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci
103(9):1640–1650. doi:10.1111/j.1349-7006.2012.02367.x
Uzdensky A, Demyanenko S, Bibov M, Sharifulina S, Kit O,
Przhedetski Y, Pozdnyakova V (2014) Expression of proteins
involved in epigenetic regulation in human cutaneous melanoma
and peritumoral skin. Tumour Biol 35(8):8225–8233. doi:10.
1007/s13277-014-2098-3
Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK,
Province P, Ding Q, You Z, Fathallah-Shaykh HM, Gillespie
GY, Zhao X, King PH, Nabors LB (2014) Expression of PRMT5
correlates with malignant grade in gliomas and plays a pivotal
role in tumor growth in vitro. J Neurooncol 118(1):61–72.
doi:10.1007/s11060-014-1419-0
Yan F, Alinari L, Lustberg ME, Katherine Martin L, CorderoNieves HM, Banasavadi-Siddegowda Y, Virk S, BarnholtzSloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki
MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley
A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G,
Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S,
Lawler S, Kaur B, Baiocchi RA (2014) Genetic validation of the
protein arginine methyltransferase PRMT5 as a candidate
therapeutic target in glioblastoma. Cancer Res 74(6):1752–1765.
doi:10.1158/0008-5472.can-13-0884
Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online
survival analysis software to assess the prognostic value of
biomarkers using transcriptomic data in non-small-cell lung
cancer. PLoS ONE 8(12):e82241. doi:10.1371/journal.pone.
0082241
Ibrahim R, Matsubara D, Osman W, Morikawa T, Goto A,
Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J,
Fukayama M, Niki T, Murakami Y (2014) Expression of
PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Hum Pathol 45(7):1397–1405.
doi:10.1016/j.humpath.2014.02.013
Shilo K, Wu X, Sharma S, Welliver M, Duan W, VillalonaCalero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W,
Otterson GA (2013) Cellular localization of protein arginine
methyltransferase-5 correlates with grade of lung tumors. Diagn
Pathol 8:201. doi:10.1186/1746-1596-8-201
Wei TY, Hsia JY, Chiu SC, Su LJ, Juan CC, Lee YC, Chen JM,
Chou HY, Huang JY, Huang HM, Yu CT (2014) Methylosome
protein 50 promotes androgen- and estrogen-independent tumorigenesis. Cell Signal 26(12):2940–2950. doi:10.1016/j.
cellsig.2014.09.014
Scoumanne A, Zhang J, Chen X (2009) PRMT5 is required for
cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res 37(15):4965–4976. doi:10.1093/nar/gkp516
Zhang HT, Zhang D, Zha ZG (1839) Hu CD (2014) Transcriptional activation of PRMT5 by NF-Y is required for cell
growth and negatively regulated by the PKC/c-Fos signaling in
prostate cancer cells. Biochim Biophys Acta 11:1330–1340.
doi:10.1016/j.bbagrm.2014.09.015
Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ,
Wang YN, Liu M, Liao HW, Shi B, Lai CC, Bedford MT, Tsai
CH, Hung MC (2011) Crosstalk between Arg 1175 methylation
and Tyr 1173 phosphorylation negatively modulates EGFRmediated ERK activation. Nat Cell Biol 13(2):174–181. doi:10.
1038/ncb2158
Lim JH, Lee YM, Lee G, Choi YJ, Lim BO, Kim YJ, Choi DK,
Park JW (2014) PRMT5 is essential for the eIF4E-mediated 50 cap dependent translation. Biochem Biophys Res Commun.
doi:10.1016/j.bbrc.2014.09.033
De Benedetti A, Graff JR (2004) eIF-4E expression and its role
in malignancies and metastases. Oncogene 23(18):3189–3199.
doi:10.1038/sj.onc.1207545
123
148. Jia Y, Polunovsky V, Bitterman PB, Wagner CR (2012) Capdependent translation initiation factor eIF4E: an emerging anticancer drug target. Med Res Rev 32(4):786–814. doi:10.1002/
med.21260
149. Jiang W, Roemer ME, Newsham IF (2005) The tumor suppressor DAL-1/4.1B modulates protein arginine Nmethyltransferase 5 activity in a substrate-specific manner.
Biochem Biophys Res Commun 329(2):522–530. doi:10.1016/j.
bbrc.2005.01.153
150. Jiang W, Newsham IF (2006) The tumor suppressor DAL-1/
4.1B and protein methylation cooperate in inducing apoptosis in
MCF-7 breast cancer cells. Mol Cancer 5:4. doi:10.1186/14764598-5-4
151. Fay MM, Clegg JM, Uchida KA, Powers MA, Ullman KS
(2014) Enhanced arginine methylation of programmed cell
death 4 protein during nutrient deprivation promotes tumor cell
viability. J Biol Chem 289(25):17541–17552. doi:10.1074/jbc.
M113.541300
152. Fisk JC, Read LK (2011) Protein arginine methylation in parasitic protozoa. Eukaryot Cell 10(8):1013–1022. doi:10.1128/ec.
05103-11
153. Liu CD, Cheng CP, Fang JS, Chen LC, Zhao B, Kieff E, Peng
CW (2013) Modulation of Epstein–Barr virus nuclear antigen
2-dependent transcription by protein arginine methyltransferase
5. Biochem Biophys Res Commun 430(3):1097–1102. doi:10.
1016/j.bbrc.2012.12.032
154. Shire K, Kapoor P, Jiang K, Hing MN, Sivachandran N, Nguyen
T, Frappier L (2006) Regulation of the EBNA1 Epstein–Barr
virus protein by serine phosphorylation and arginine methylation. J Virol 80(11):5261–5272. doi:10.1128/jvi.02682-05
155. Doueiri R, Anupam R, Kvaratskhelia M, Green KB, Lairmore
MD, Green PL (2012) Comparative host protein interactions
with HTLV-1 p30 and HTLV-2 p28: insights into difference in
pathobiology of human retroviruses. Retrovirology 9:64. doi:10.
1186/1742-4690-9-64
156. Boulanger MC, Liang C, Russell RS, Lin R, Bedford MT,
Wainberg MA, Richard S (2005) Methylation of Tat by PRMT6
regulates human immunodeficiency virus type 1 gene expression. J Virol 79(1):124–131. doi:10.1128/jvi.79.1.124-131.2005
157. Beltran-Alvarez P, Espejo A, Schmauder R, Beltran C, Mrowka
R, Linke T, Batlle M, Perez-Villa F, Perez GJ, Scornik FS,
Benndorf K, Pagans S, Zimmer T, Brugada R (2013) Protein
arginine methyl transferases-3 and -5 increase cell surface expression of cardiac sodium channel. FEBS Lett
587(19):3159–3165. doi:10.1016/j.febslet.2013.07.043
158. Yost JM, Korboukh I, Liu F, Gao C, Jin J (2011) Targets in
epigenetics: inhibiting the methyl writers of the histone code.
Curr Chem Genomics 5(Suppl 1):72–84. doi:10.2174/
1875397301005010072
159. Copeland RA, Solomon ME, Richon VM (2009) Protein
methyltransferases as a target class for drug discovery. Nat Rev
Drug Discov 8(9):724–732. doi:10.1038/nrd2974
160. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer
CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L,
Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC,
Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock
RM (2011) Selective killing of mixed lineage leukemia cells by
a potent small-molecule DOT1L inhibitor. Cancer Cell
20(1):53–65. doi:10.1016/j.ccr.2011.06.009
161. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A,
Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J,
Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-awar
R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE,
Schapira M (2012) Catalytic site remodelling of the DOT1L
The PRMT5 arginine methyltransferase
162.
163.
164.
165.
166.
167.
168.
methyltransferase by selective inhibitors. Nat Commun 3:1288.
doi:10.1038/ncomms2304
Dhar SS, Lee SH, Kan PY, Voigt P, Ma L, Shi X, Reinberg D,
Lee MG (2012) Trans-tail regulation of MLL4-catalyzed H3K4
methylation by H4R3 symmetric dimethylation is mediated by a
tandem PHD of MLL4. Genes Dev 26(24):2749–2762. doi:10.
1101/gad.203356.112
Tsai WW, Niessen S, Goebel N, Yates JR 3rd, Guccione E,
Montminy M (2013) PRMT5 modulates the metabolic response
to fasting signals. Proc Natl Acad Sci USA 110(22):8870–8875.
doi:10.1073/pnas.1304602110
Tae S, Karkhanis V, Velasco K, Yaneva M, Erdjument-Bromage
H, Tempst P, Sif S (2011) Bromodomain protein 7 interacts with
PRMT5 and PRC2, and is involved in transcriptional repression
of their target genes. Nucleic Acids Res 39(13):5424–5438.
doi:10.1093/nar/gkr170
Neuenkirchen N, Chari A, Fischer U (2008) Deciphering the
assembly pathway of Sm-class U snRNPs. FEBS Lett
582(14):1997–2003. doi:10.1016/j.febslet.2008.03.009
Gonsalvez GB, Rajendra TK, Tian L, Matera AG (2006) The
Sm-protein methyltransferase, dart5, is essential for germ-cell
specification and maintenance. Curr Biol 16(11):1077–1089.
doi:10.1016/j.cub.2006.04.037
Friesen WJ, Wyce A, Paushkin S, Abel L, Rappsilber J, Mann
M, Dreyfuss G (2002) A novel WD repeat protein component of
the methylosome binds Sm proteins. J Biol Chem
277(10):8243–8247. doi:10.1074/jbc.M109984200
Anne J, Ollo R, Ephrussi A, Mechler BM (2007) Arginine
methyltransferase Capsuleen is essential for methylation of
spliceosomal Sm proteins and germ cell formation in
Drosophila. Development 134(1):137–146. doi:10.1242/dev.
02687
169. Li Z, Yu J, Hosohama L, Nee K, Gkountela S, Chaudhari S,
Cass AA, Xiao X, Clark AT (2014) The Sm protein methyltransferase PRMT5 is not required for primordial germ cell
specification in mice. EMBO J. doi:10.15252/embj.201489319
170. Ren J, Wang Y, Liang Y, Zhang Y, Bao S, Xu Z (2010)
Methylation of ribosomal protein S10 by protein-arginine
methyltransferase 5 regulates ribosome biogenesis. J Biol Chem
285(17):12695–12705. doi:10.1074/jbc.M110.103911
171. Guo Z, Zheng L, Xu H, Dai H, Zhou M, Pascua MR, Chen QM,
Shen B (2010) Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol
6(10):766–773. doi:10.1038/nchembio.422
172. Wei TY, Hsia JY, Chiu SC, Su LJ, Juan CC, Lee YC, Chen JM,
Chou HY, Huang JY, Huang HM, Yu CT (2014) Methylosome
protein 50 promotes androgen- and estrogen-independent tumorigenesis. Cell Signal. doi:10.1016/j.cellsig.2014.09.014
173. Anne J, Mechler BM (2005) Valois, a component of the nuage
and pole plasm, is involved in assembly of these structures, and
binds to Tudor and the methyltransferase Capsuleen. Development 132(9):2167–2177. doi:10.1242/dev.01809
174. Lacroix M, Messaoudi SE, Rodier G, Le Cam A, Sardet C, Fabbrizio E (2008) The histone-binding protein COPR5 is required for
nuclear functions of the protein arginine methyltransferase
PRMT5. EMBO Rep 9(5):452–458. http://www.nature.com/
embor/journal/v9/n5/suppinfo/embor200845_S1.html
175. Nishioka K, Reinberg D (2003) Methods and tips for the purification of human histone methyltransferases. Methods (San
Diego, Calif) 31(1):49–58 pii: S1046202303000872
123
View publication stats